Using the TCGA, we found that head and neck cancer patients have higher MK2 gene expression compared to non-cancer patients and MK2 transcript levels increased with worsening tumor grade (Fig. 1A and B). This evidence concerns the gene MAPKAPK2 and neoplasm.